Mounjaro Emerges India’s Top‑Selling Drug in October

In a breakthrough for India’s pharmaceutical market, the drug Mounjaro — manufactured by Eli Lilly and Company — became the highest‑value selling drug in India for October 2025, crossing ₹1 billion in monthly sales. This rapid rise, just months after its launch in India, reflects shifting dynamics in chronic disease treatment, rising demand for weight‑loss medications, and evolving pharma‑market trends. For aspirants reviewing current affairs, this development sits at the intersection of healthcare, business, and policy.

Key Facts & Figures

  • Mounjaro recorded ≈ ₹1 billion (≈ $11.38 million) in sales in India during October 2025.
  • Since its launch in India in March 2025, cumulative revenues for Mounjaro stood at about ₹3.33 billion up to end of October.
  • In October, by volume, Mounjaro’s consumption was approximately ten times that of its competitor Wegovy (launched June 2025).
  • The drug is positioned for both diabetes management and weight‑loss treatment, leveraging the dual hormone‑target mechanism of action (GLP‑1 & GIP).

Pricing dynamics: its launch included different formulations including vials and later pen devices; initial starting dose packs were priced around ₹14,000 for 2.5 mg in India.

Shift in Treatment & Market Demand

  • The success of Mounjaro signals that Indian healthcare is increasingly embracing therapies for obesity and metabolic disorders, not just traditional diseases.
  • With rising rates of diabetes and obesity in India, such therapies are gaining fast traction.

Pharma Market Disruption

  • A relatively new entrant reaching top‑selling status in less than a year demonstrates how fast the Indian pharmaceutical market can shift.
  • Legacy brands and treatments may face competition from newer therapeutic categories.

Health Policy & Access

  • The affordability and access of such advanced drugs in India raise questions and opportunities around insurance coverage, out‑of‑pocket costs, and public health readiness for lifestyle‑related conditions.
Shivam

As a Content Executive Writer at Adda247, I am dedicated to helping students stay ahead in their competitive exam preparation by providing clear, engaging, and insightful coverage of both major and minor current affairs. With a keen focus on trends and developments that can be crucial for exams, researches and presents daily news in a way that equips aspirants with the knowledge and confidence they need to excel. Through well-crafted content, Its my duty to ensures that learners remain informed, prepared, and ready to tackle any current affairs-related questions in their exams.

Recent Posts

Dr Colleen Begg Receives 2026 Prince William Award for Conservation in Africa

Dr Colleen Begg from South Africa has won the 2026 Prince William Award for Conservation…

1 day ago

INSA President Shekhar C. Mande Appointed to UN 10-Member Group on Science and Technology for SDGs

Professor Shekhar C. Mande, President of the Indian National Science Academy (INSA), has been appointed…

1 day ago

National Gopal Ratna Award 2026: Winners, Categories, Prize Money and Key Details

The winners of the National Gopal Ratna Awards (NGRA) 2026 have been announced. It aims…

1 day ago

India’s Cheetah Population Rises to 62 as Botswana-Born Cheetah Gives Birth to Four Cubs

Four cheetah cubs have been born to a female cheetah in the wild, increasing the…

1 day ago

India Launches Indigenous Bird Flu Vaccine to Protect Poultry Farmers

India has developed its very own H5N1 subtype Bird Flu Vaccine for Chickens. On November…

1 day ago

PM Narendra Modi Inaugurates First SCO Civilisational Dialogue Forum in New Delhi

On 20 th November 2026, the Prime Minister Narendra Modi formally opened the First Shanghai…

1 day ago